Lv4
406 积分 2025-09-18 加入
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review
16小时前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
8天前
已完结
Immunotherapy for early-stage triple-negative breast cancer
8天前
已完结
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
9天前
已完结
Dual-payload antibody-drug conjugates: Taking a dual shot
9天前
已完结
Homogeneousmulti-payloadantibody-drugconjugates
9天前
已完结
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
14天前
已完结
Antibody–drug conjugates come of age in oncology
16天前
已完结
Mechanisms of Resistance to Antibody-Drug Conjugates
17天前
已完结
Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014-2023
17天前
已完结
皖公网安备34019202002308
